Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cygnal Therapeutics
Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2016
Status: Merged
BioCentury | Oct 19, 2023
Deals
Flagship portfolio consolidation continues with Laronde-Senda
Pair of well-funded Flagship portfolio companies will unite in Sail Biomedicines to develop programmable medicines
BioCentury | Jun 29, 2022
Management Tracks
New CEOs at Dunad and Cargene
Plus Vickers becomes CEO at MSKCC, and updates from Paradigm and DTx
BioCentury | May 19, 2022
Deals
Flagship revisits company combination strategy with Sonata
The Cygnal-Inzen mashup is taking a microenvironment-focused approach to cancer, fibrosis and autoimmunity
BioCentury | Jun 22, 2021
Management Tracks
Wigerinck to leave Galapagos; plus Kymera, Alladapt, Nurix, Alchemab, Novome and more
Piet Wigerinck will step down this year after serving as CSO for nine years at Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), overseeing the Belgian biotech’s programs from the discovery of
BioCentury | Apr 8, 2021
Management Tracks
Fineberg to lead SVB Leerink’s structured finance group; plus Gimv, Syncona, Tessera, NKGen and more
SVB Leerink hired Andrew Fineberg as managing director to lead the firm’s new structured finance group. Fineberg joins from MTS Health Partners, where he served as partner and head of royalty
BioCentury | Dec 21, 2019
Company News
Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more
BioCentury | Oct 8, 2019
Emerging Company Profile
Flagship unveils Cygnal, a nervy take on cancer, inflammation
Flagship’s Cygnal is deploying $65M to drug neurological drivers of cancer, inflammation
BioCentury | Apr 11, 2019
Targets & Mechanisms
A venture view of biological white space
VCs on BioCentury’s SAB weigh in on biological whitespace
Items per page:
1 - 9 of 9